571 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
LLY Eli Lilly and Company $105.71 $113.53B Downtrend
Article Searches
Roche Submits sBLA to FDA for Label Expansion of Kadcyla http://www.zacks.com/stock/news/352051/roche-submits-sbla-to-fda-for-label-expansion-of-kadcyla?cid=CS-ZC-FT-352051 Feb 05, 2019 - Roche (RHHBY) submits sBLA for Kadcyla to the FDA for adjuvant treatment of patients with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.
Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy http://www.zacks.com/stock/news/351848/teva-gains-positive-chmp-opinion-for-migraine-drug-ajovy?cid=CS-ZC-FT-351848 Feb 04, 2019 - Teva (TEVA) receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP), advocating a marketing approval for its new migraine medicine, Ajovy.
Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat http://www.zacks.com/stock/news/351653/novo-nordisk-nvo-q4-earnings-miss-estimates-revenues-beat?cid=CS-ZC-FT-351653 Feb 01, 2019 - Novo Nordisk (NVO) fourth-quarter 2018 results mainly benefit from strong performance by Ozempic.
Lilly (LLY) Hits 52-Week High, Can the Run Continue? http://www.zacks.com/stock/news/351514/lilly-lly-hits-52-week-high-can-the-run-continue?cid=CS-ZC-FT-351514 Feb 01, 2019 - Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Pfizer Pivots to Cancer Drugs for Growth https://www.wsj.com/articles/pfizer-pivots-to-cancer-drugs-for-growth-11548601200?mod=pls_whats_news_us_business_f Jan 27, 2019 - Pfizer is seeking a new round of growth by treating cancer and is among the big pharmaceutical companies trying to expand in oncology.
Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV http://www.zacks.com/stock/news/349786/pharma-stock-roundup-jnj-bmys-q4-earnings-study-failures-at-lly-abbv?cid=CS-ZC-FT-349786 Jan 25, 2019 - J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.
Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds http://www.zacks.com/stock/news/349760/merck-kgaa-gives-vertex-rights-to-two-gene-editing-compounds?cid=CS-ZC-FT-349760 Jan 25, 2019 - Merck KGaA (MKGAF) inks an exclusive licensing agreement with Vertex for two DNA-dependent protein kinase inhibitors in the field of gene editing for six specific genetic disease indications.
Moderna's Hot New mRNA Technology Has Competition https://www.fool.com/investing/2019/01/24/modernas-hot-new-mrna-technology-has-competition.aspx?source=iedfolrf0000001 Jan 24, 2019 - They're largely flying under the radar of most investors.
Sanofi's (SNY) Influenza Vaccine Gets FDA Approval for Kids http://www.zacks.com/stock/news/349470/sanofis-sny-influenza-vaccine-gets-fda-approval-for-kids?cid=CS-ZC-FT-349470 Jan 24, 2019 - Sanofi's (SNY) influenza vaccine, Fluzone Quadrivalent (0.5mL dose), gains an FDA nod for treating children in six to 35-month age group.
Does Johnson & Johnson's Grim Outlook Spell Trouble for Big Pharma Stocks? https://www.fool.com/investing/2019/01/24/does-johnson-johnsons-grim-outlook-spell-trouble-f.aspx?source=iedfolrf0000001 Jan 24, 2019 - Here's why comments from J&J executives about the future of pharmaceuticals made investors so nervous.

Pages: 1...345678910111213...58

<<<Page 8>